tiprankstipranks
Trending News
More News >
Advertisement
Advertisement
PremiumCompany AnnouncementsInhibrx Biosciences Advances Cancer Treatment with INBRX-106 Study Update
2M ago
Premium
Company Announcements
Inhibrx’s Phase 2 Study on INBRX-109: A Potential Breakthrough in Chondrosarcoma Treatment
2M ago
Premium
Company Announcements
Inhibrx’s Phase 1 Study of INBRX-109: A Potential Game-Changer in Cancer Treatment
2M ago
Inhibrx reports positive topline results from registrational trial of ozekibart
PremiumThe FlyInhibrx reports positive topline results from registrational trial of ozekibart
2M ago
Inhibrx trading halted, news pending
Premium
The Fly
Inhibrx trading halted, news pending
2M ago
Premium
Company Announcements
Inhibrx Biosciences Reports Q2 2025 Financial Results
4M ago
Inhibrx appoint Carlos Bais as Chief Scientific Officer
PremiumThe FlyInhibrx appoint Carlos Bais as Chief Scientific Officer
9M ago
Inhibrx reports Q4 EPS ($3.09) vs. ($6.93) last year
Premium
The Fly
Inhibrx reports Q4 EPS ($3.09) vs. ($6.93) last year
9M ago
Premium
Company Announcements
Inhibrx Biosciences Reports Promising Trial Results for INBRX-109
11M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100